Kimie Sai

List of Publications by Year in Descending Order

38 papers	1,538 citations	21 h-index	39 g-index
41 ext. papers	1,675 ext. citations	3.6 avg, IF	3.17 L-index

#	Paper	IF	Citations
38	Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. *Clinical and Translational Science*, **2021**, 14, 1002-1014	4.9	3
37	Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial Data. *Therapeutic Innovation and Regulatory Science*, **2021**, 55, 523-538	1.2	0
36	Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials. *British Journal of Clinical Pharmacology*, **2019**, 85, 1270-1282	3.8	2
35	A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. *Drug Metabolism and Pharmacokinetics*, **2016**, 31, 467-470	2.2	11
34	Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. *International Journal of Clinical Pharmacy*, **2015**, 37, 537-45	2.3	8
33	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. *BMC Cancer*, **2015**, 15, 718	4.8	5
32	A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale. *Pharmacoepidemiology and Drug Safety*, **2014**, 23, 984-8	2.6	23
31	Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect. *PLoS ONE*, **2014**, 9, e105160	3.7	4
30	Evaluation of two Japanese regulatory actions using medical information databases: a PDear DoctorRetter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel. *Journal of Clinical Pharmacy and Therapeutics*, **2014**, 39, 361-7	2.2	9
29	An algorithm for the identification of heparin-induced thrombocytopenia using a medical information database. *Journal of Clinical Pharmacy and Therapeutics*, **2013**, 38, 423-8	2.2	6
28	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. *Journal of Bioscience and Bioengineering*, **2013**, 116, 768-73	3.3	8
27	Development of a detection algorithm for statin-induced myopathy using electronic medical records. *Journal of Clinical Pharmacy and Therapeutics*, **2013**, 38, 230-5	2.2	11
26	Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 967-88	5.5	19
25	Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. *British Journal of Clinical Pharmacology*, **2010**, 70, 222-33	3.8	41
24	CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. *Drug Metabolism and Disposition*, **2010**, 38, 2100-4	4	36
23	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. *Cancer Chemotherapy and Pharmacology*, **2010**, 66, 95-105	3.5	50
22	Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. *Drug Metabolism and Disposition*, **2009**, 37, 272-6	4	21

21	Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. *Cancer Letters*, **2008**, 261, 165-71	9.9	39
20	Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. *Drug Metabolism and Pharmacokinetics*, **2008**, 23, 139-47	2.2	23
19	Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 529-37	3.5	19
18	Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment **2008**, 267-286		
17	A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. *Clinical Chemistry*, **2007**, 53, 356-8	5.5	9
16	Haplotypes and a novel defective allele of CES2 found in a Japanese population. *Drug Metabolism and Disposition*, **2007**, 35, 1865-72	4	22
15	Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 456-61	2.2	26
14	Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. *Pharmacogenetics and Genomics*, **2007**, 17, 497-504	1.9	227
13	MX, a by-product of water chlorination, lacks in vivo genotoxicity in gpt delta mice but inhibits gap junctional intercellular communication in rat WB cells. *Environmental and Molecular Mutagenesis*, **2006**, 47, 48-55	3.2	15
12	Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 109-21	2.2	32
11	Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences. *Annals of Human Genetics*, **2006**, 70, 605-22	2.2	17
10	Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). *Drug Metabolism and Disposition*, **2005**, 33, 1482-7	4	40
9	Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. *Human Mutation*, **2004**, 23, 100	4.7	119
8	UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 501-15	6.1	209
7	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. *Pharmacogenetics and Genomics*, **2003**, 13, 741-57		126
6	An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. *Biomedical Chromatography*, **2002**, 16, 209-18	1.7	32
5	Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5Runtranslated region and exon 28. *Drug Metabolism and Disposition*, **2002**, 30, 363-4	4	90
4	CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. *Drug Metabolism and Pharmacokinetics*, **2002**, 17, 150-6	2.2	45

3	Inhibition of apoptosis by pentachlorophenol in v-myc-transfected rat liver epithelial cells: relation to down-regulation of gap junctional intercellular communication. *Cancer Letters*, **2001**, 173, 163-74	9.9	44
2	Prevention of the down-regulation of gap junctional intercellular communication by green tea in the liver of mice fed pentachlorophenol. *Carcinogenesis*, **2000**, 21, 1671-6	4.6	82
1	Inhibitory effect of pentachlorophenol on gap junctional intercellular communication in rat liver epithelial cells in vitro. *Cancer Letters*, **1998**, 130, 9-17	9.9	47